Miro Brajenovic

Miro Brajenovic is the CEO of Thelium Therapeutics. Miro has over 20 years of experience in the biotech industry, including senior leadership roles at CERo Therapeutics, Cell Design Labs, and Pfizer.

Brajenovic started their career as a PhD student at the University of Heidelberg, where they studied biochemistry and genetics. Miro went on to become a graduate scientist and entrepreneur at Cellzome, before joining Genentech as their Chief of Staff in 2004.

At Genentech, Brajenovic oversaw operations for the company's R&D department. In 2014, they left to join Medivation as their Director of Project Management. Pfizer acquired Medivation in September 2016, and Brajenovic continued to lead the company's project management team until March 2017.

Brajenovic then joined Cell Design Labs as their Head of Project and Alliance Management. Miro was responsible for leading the company's cell therapy portfolio and external alliances. In 2019, Cell Design Labs was acquired by Kite/Gilead, and Brajenovic played a key role in aligning CDL and Kite Research projects post-acquisition.

Most recently, Brajenovic has been serving as the VP of Corporate Strategy and Operations at CERo Therapeutics. In May 2021, they were appointed CEO of Thelium Therapeutics.

Miro Brajenovic has a Ph.D. in Biology from Heidelberg University and a Diploma in Biology from the same school.

Some individuals on their team include Petr Jansa - Head, Medicinal Chemistry, Roman Sakowicz - Chief Technology Officer & Head, Discovery, and Vallen Graham - Co-Founder & Head, Research.